Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.

Leuk Res Rep · 2022 · PMC9098391 · PMID 35572915

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

in 2019, WM patients who received rituximab maintenance showed a trend to longer time to next treatment and significantly longer OS (not reached vs 10.1 years, p = 0.02) [27] .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.